Cel-Sci (NYSEAMERICAN:CVM) Shares Down 4.4% – What’s Next?

Shares of Cel-Sci Corporation (NYSEAMERICAN:CVM) traded down 4.4% during trading on Tuesday . The stock traded as low as $3.69 and last traded at $3.70. 17,446 shares changed hands during trading, a decline of 61% from the average session volume of 44,651 shares. The stock had previously closed at $3.87.

Cel-Sci Trading Down 4.4%

The stock has a market capitalization of $31.30 million, a P/E ratio of -0.38 and a beta of 0.85. The stock’s fifty day moving average price is $5.05 and its two-hundred day moving average price is $7.04. The company has a current ratio of 1.39, a quick ratio of 1.35 and a debt-to-equity ratio of 0.45.

Cel-Sci (NYSEAMERICAN:CVM) last released its earnings results on Tuesday, December 23rd. The company reported ($0.76) EPS for the quarter. Equities research analysts forecast that Cel-Sci Corporation will post -0.29 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CVM. HighTower Advisors LLC bought a new stake in shares of Cel-Sci in the 4th quarter valued at about $53,000. HRT Financial LP bought a new position in Cel-Sci during the 4th quarter worth approximately $60,000. XTX Topco Ltd purchased a new position in Cel-Sci in the 4th quarter worth approximately $66,000. US Bancorp DE purchased a new position in Cel-Sci in the 3rd quarter worth approximately $80,000. Finally, Renaissance Technologies LLC bought a new stake in Cel-Sci in the fourth quarter valued at approximately $81,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.